First-in-class pan caspase inhibitor developed for the treatment of liver disease

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6779-6782

  Linton, Steven D ^a   Aja, Teresa ^a   Armstrong, Robert A ^a   Bai, Xu ^a   Chen, Long Shiuh ^a   Chen, Ning ^a   Ching, Brett ^a   Contreras, Patricia ^a   Diaz, Jose Luis ^a   Fisher, Craig D ^a   Fritz, Lawrence C ^a   Gladstone, Patricia ^a   Groessl, Todd ^a   Gu, Xin ^a   Herrmann, Julia ^a   Hirakawa, Brad P ^a   Hoglen, Niel C ^a   Jahangiri, Kathy G ^a   Kalish, Vincent J ^a   Karanewsky, Donald S ^a   Kodandapani, Lalitha ^a   Krebs, Joseph ^a   McQuiston, Jeff ^a   Meduna, Steven P ^a   Nalley, Kip ^a   Robinson, Edward D ^a   Sayers, Robert O ^a   Sebring, Kristen ^a   Spada, Alfred P ^a   Ternansky, Robert J ^a   Tomaselli, Kevin J ^a   Ullman, Brett R ^a   Valentino, Karen L ^a   Weeks, Suzanne ^a   Winn, David ^a   Wu, Joe C ^a   Yeo, Pauline ^a   Zhang, Cheng Zhi ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; CASPASE INHIBITOR; IDN 1965; IDN 5370; UNCLASSIFIED DRUG;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL ACTIVITY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; LIVER DISEASE; STRUCTURE ACTIVITY RELATION;

ADULT; ALANINE TRANSAMINASE; ANIMALS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL AVAILABILITY; CASPASE 3; CASPASES; CHOLESTASIS; CLINICAL TRIALS, PHASE I; HALF-LIFE; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; JURKAT CELLS; LIVER; LIVER DISEASES; MICE; PENTANOIC ACIDS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27444447723     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050307e     Document Type: Article

References (37)

1. (a) Ellis, R. E.; Yuan, J.; Horvitz, H. R. Mechanisms and Functions of Cell Death. Annu. Rev. Cell Biol. 1991, 7, 663-698.
2. (b) Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000 407, 810-816.
3. (c) Galle, P. R. Apoptosis in liver disease. J. Hepatol. 1997, 27, 405-412.
4. Reed, J. Apoptosis based therapies. Nat. Rev. Drug Discovery 2002 1, 111-121.
5. (a) For nomenclature of the caspase family, see: Alnemri, E. S.; Livingston, D. J.; Nicholson, D. W.; Salvesen, G.; Thornberry, N. A.; Wong, W. W.; Yuan, J.-Y. Human ICE/ced-3 protease nomenclature. Cell 1996 87, 171.
6. (b) Black, R. A.; Kronheim S. R.; Sleath, P. R. Activation of interleukin-1β by a co-induced protease. FEBS Lett. 1989, 247, 386-390.
7. (c) Thornberry, N. A. Caspases: Key mediators of apoptosis. Chem. Biol. 1998 5, R97-103.
8. (d) Fuentes-Prior, P.; Salvesen, G. S. The protein structures that shape caspase activity, specificity, activation, and inhibition. Biochem. J. 2004, 384, 201-232.
9. Earnshaw, W. C.; Martins, L. M.; Kaufmann, S. H. Mammalian caspases: structure, activation, substrates and function during apoptosis. Annu. Rev. Biochem. 1999, 68, 383-424.
10. (a) Talanian, R. V.; Brady, K. D.; Cryns, V. L. Caspases as targets for antiinflammatory and anti-apoptotic drug discovery. J. Med. Chem. 2000, 43, 3351-3371.
11. (b) Ashwell, S. Caspases: Recent advances in small molecule inhibitors. Exp. Opin. Ther. Pat. 2001, 11, 1593-1603.
12. (a) Cai, S. X.; Guan, L.; Jia, S.; Wang, Y.; Yang, W.; Tseng, B.; Drewe, J. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. Bioorg. Med. Chem. Lett. 2004, 14, 5295-5300.
13. (b) Wang, Y.; Guan, L.; Jia, S.; Tseng, B.; Drewe, J.; Cai, S. X. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 α-amino acid by an α-hydroxy acid. Bioorg. Med. Chem. Lett. 2005, 15, 1379-1383.
14. (c) Isabel, E.; Black, W. C.; Bayly, C. I.; Grimm, E. L.; Janes, M. K.; McKay, D. J.; Nicholson, D. W.; Rasper, D. M.; Renaud, J.; Roy, S.; Tam, J.; Thornberry, N. A.; Vaillancourt, J. P.; Xanthoudakis, S.; Zamboni, R. Nicotinyl aspartyl ketones as inhibitors of caspase-3. Bioorg. Med. Chem. Lett. 2003, 13, 2137-2140.
15. (d) Colucci, J.; Giroux, A.; Zhu, Y.; Bouche, M.; Pikounis, B.; Xanthoudakis, S.; Roy, S.; Rigby, M.; Zamboni, R.; Robertson, G. S.; Ng, G. Y.; Nicholson, D. W.; Fluckiger, J. P.; Toulmond, S.; Tang, K.; Bureau, Y.; Ashdown, H.; Degen, S.; O'Donnell, R.; Tam, J.; Han, Y. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br. J. Pharmacol. 2004 141, 689-697.
16. (e) Han, Y.; Giroux, A.; Grimm, E. L.; Aspiotis, R.; Francoeur, S.; Bayly, C. I.; McKay, D. J.; Roy, S.; Xanthoudakis, S.; Vaillancourt, J. P.; Rasper, D. M.; Tam, J.; Tawa, P.; Thornberry, N. A.; Paterson, E. P.; Garcia-Calvo, M.; Becker, J. W.; Rotonda, J.; Nicholson, D. W.; Zamboni, R. J. Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 805-808.
17. (f) Han, Y.; Giroux, A.; Colucci, J.; Bayly, C. I.; McKay, D. J.; Roy, S.; Xanthoudakis, S.; Vaillancourt, J.; Rasper, D. M.; Tam, J.; Tawa, P.; Nicholson, D. W.; Zamboni, R. J. Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1173-1180.
18. (a) Graczyk, P. P. Caspase inhibitors as antiinflammatory and antiapoptotic agents. Prog. Med. Chem. 2002, 39, 1-72.
19. (b) O'Brien, Tom; Lee, Dennis. Prospects for caspase inhibitors. Mini-Rev. Med. Chem. 2004, 4, 153-165.
20. (c) Linton, S. D. Caspase inhibitors: A pharmaceutical industry perspective. Curr. Topics Med. Chem., in press.
21. (a) Bai, X.; Karanewsky, D. S. C-terminal modified (N-substituted)-2- indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases. US Patent 5,877,197, Feb 9, 1999.
22. (b) Bai, X.; Karanewsky, D. S. C-terminal modified (N-substituted)-2- indolylcarbonyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases. US Patent 6,184,244, Feb 6, 2001.
23. Deckwerth, T. L.; Adams, L. M.; Wiessner, C.; Allegrini, P. R.; Rudin, M.; Sauter, A.; Hengerer, B.; Sayers, R. O.; Rovelli, G.; Aja, T.; May, R.; Nalley, K.; Linton, S. D.; Karanewsky, D. S.; Wu, J. C.; Roggo, S.; Schmitz, A.; Contreras, P. C.; Tomaselli, K. J. Long-term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors. Drug Dev. Res. 2001, 52, 579-586.
24. indoles: A new class of potent broad spectrum caspase inhibitors with in vivo activity in the pMCAO model. Abstracts of Papers, 221st American Chemical Society National Meeting, San Diego, CA, United States, April 1-5, 2001.
25. (a) Linton, S. D.; Karanewsky, D. S.; Ternansky, R. J.; Wu, J. C.; Pham, B.; Kodandapani, L.; Smidt, R.; Diaz, J. L.; Fritz, L. C.; Tomaselli, K. J. Acyl dipeptides as reversible caspase inhibitors. Part 1: Initial lead optimization. Bioorg. Med. Chem. Lett. 2002, 12, 2969-2971.
26. (b) Linton, S. D.; Karanewsky, D. S.; Ternansky, R. J.; Chen, N.; Guo, X.; Jahangiri, K. G.; Kalish, V. J.; Meduna, S. P.; Robinson, E. D.; Ullman, B. R.; Wu, J. C.; Pham, B.; Kodandapani, L.; Smidt, R.; Diaz, J. L.; Fritz, L. C.; Krosigk, U.; Roggo, S.; Schmitz, A.; Tomaselli, K. J. Acyl dipeptides as reversible caspase inhibitors. Part 2: Further optimization. Bioorg Med. Chem. Lett. 2002, 12, 2973-2975.
27. (c) Ullman, B. R.; Aja, T.; Deckwerth, T. L.; Diaz, J. L.; Herrman, J.; Kalish, V. J.; Karanewsky, D. S.; Meduna, S. P.; Nalley, K.; Robinson, E. D.; Roggo, S. P.; Sayers, R. O.; Schmitz, A.; Ternansky, R. J.; Tomaselli, K. J.; Wu, J. C. Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications. Bioorg. Med. Chem. Lett. 2003, 13, 3623-3626.
28. (a) Brady, K. D. Bimodal inhibition of caspase-1 by aryloxymethyl and acyloxymethyl ketones. Biochemistry 1998, 37, 8508-8515.
29. (b) Brady, K. D.; Giegel, D. A.; Grinnell, C.; Lunney, E.; Talanian, R. V.; Wong, W.; Walker, N. A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones. Bioorg. Med. Chem. 1999, 7, 621-631.
30. Linton, S. D.; Aja, T.; Allegrini, P. R.; Deckwerth, T. L.; Diaz, J. L.; Hengere, B.; Herrman, J.; Jahangiri, K. G.; Kallen, J.; Karanewsky, D. S.; Meduna, S. P.; Nalley, K.; Robinson, E. D.; Roggo, S.; Rovelli, G.; Sauter, A.; Sayers, R. O.; Schmitz, A.; Smidt, R.; Ternansky, R. J.; Tomaselli, K. J.; Ullman, B. R.; Wiessner, C.; Wu, J. C. Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. Bioorg. Med. Chem. Lett. 2004, 14, 2685-2691.
31. Wu, J. C.; Fritz, L. C. Irreversible caspase inhibitors: tools for studying apoptosis. Methods: A Companion Methods Enzymol. 1999, 17, 320-328.
32. Armstrong, R. C.; Aja, T.; Xiang J.; Gaur S.; Krebs, J. F.; Hoang, K.; Bai, X.; Korsmeyer, S. J.; Karanewsky, D. S.; Fritz, L. C.; Tomaselli, K. J. Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J. Biol. Chem. 1996, 271, 16850-16855.
33. Kunstle, G.; Leist, M.; Uhlig, S.; Revesz, L.; Feifel, R.; MacKenzie, A.; Wendel, A. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-α. Immunol. Lett. 1997, 55, 5-10.
34. Hoglen, N. C.; Chen, L. S.; Fisher, C. D.; Hirakawa, B. P.; Groessl, T.; Contreras, P. C. Characterization of IDN-6556 (3-{2-[(2-ieri-Butyl- phenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy) -pentanoic acid): a liver-targeted caspase inhibitor. J. Pharm. Exp. Ther. 2003, 309, 634-640.
35. Canbay, A.; Feldstein, A.; Baskin-Bey, E.; Bronk, S. F.; Gores, G. J. The caspase inhibitor IDN-6556 attenuates hepatic injury and flbrosis in the bile duct ligated mouse. J. Pharm. Exp. Ther. 2004, 308, 1191-1196.
36. Valentino, K. L.; Gutierrez, M.; Sanchez, R.; Winship, M. J.; Shapiro, D. A. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharm. Ther. 2003, 41, 441-449.
37. Schiff, E. R.; Pockros, P.; Shiftman, M. L.; McHutchinson, J.; Gish, R.; Afdhal, N. H.; Makhviladze, M.; Huyghe, M.; Hecht, D.; Oltersdorf, T.; Shapiro, D. Oral IDN-6556, an anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients. Gastroenterology 2004, 126, Suppl. 2: A-668.